Sentinel lymph node biopsy in the management of ductal carcinoma in situ

Clinical Breast Cancer

Volumn 6, Issue 3, 2005, Pages 216-222

  Zujewski, JoAnne ^a   Eng Wong, Jennifer ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cytokeratin; Lymphovascular invasion; Microinvasion

Indexed keywords

CYTOKERATIN; EOSIN; HEMATOXYLIN; TAMOXIFEN;

AXILLARY LYMPH NODE; BREAST CANCER; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CARCINOMA IN SITU; CLINICAL TRIAL; HUMAN; IMMUNOHISTOCHEMISTRY; LACRIMAL DUCT; MAMMOGRAPHY; MASTECTOMY; METASTASIS; MULTIPLE CANCER; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW; SENTINEL LYMPH NODE BIOPSY; AXILLA; BREAST TUMOR; LYMPH NODE; LYMPH NODE METASTASIS; PAGET NIPPLE DISEASE; PATHOLOGY;

AXILLA; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; SENTINEL LYMPH NODE BIOPSY;

EID: 32944471748     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2005.n.023     Document Type: Review

References (67)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10-30.
2. Cady B, Stone MD, Schuler JG, et al. The new era in breast cancer. Invasion, size, and nodal involvement dramatically decreasing as a result of mammographic screening. Arch Surg 1996; 131:301-308.
3. National Cancer Institute Surveillance, Epidemiology, and End Results Program. SEER Cancer Statistics Review, 1975-2002. Bethesda, MD: NCI, 2005. Available at: http://seer.cancer.gov/csr/1975_2002/. Accessed October 2003.
4. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999; 353:1993-2000.
5. Wickerham DL. Ductal carcinoma-in-situ. J Clin Oncol 2001; 19(suppl):98S-100S.
6. Fisher ER, Costantino J, Fisher B, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) protocol B-17. Intraductal carcinoma (ductal carcinoma in situ). The National Surgical Adjuvant Breast and Bowel Project Collaborating Investigators. Cancer 1995; 75:1310-1319.
7. Julien JP, Bijker N, Fentiman IS, et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet 2000; 355:528-533.
8. Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998; 16:441-452.
9. Houghton J, George WD, Cuzick J, et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 2003; 362:95-102.
10. Burstein HJ, Polyak K, Wong JS, et al. Ductal carcinoma in situ of the breast. N Engl J Med 2004; 350:1430-1441.
11. Schwartz GF: The current treatment of ductal carcinoma in situ. Breast J 2001; 7:308-310.
12. Morrow M, Strom EA, Bassett LW, et al. Standard for the management of ductal carcinoma in situ of the breast (DCIS). CA Cancer J Clin 2002; 52:256-276.
13. Baxter NN, Virnig BA, Durham SB, et al. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst 2004; 96:443-448.
14. Chlebowski RT, Col N, Winer EP, et al. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol 2002; 20:3328-3343.
15. Cody HS, Van Zee KJ. Point: Sentinel lymph node biopsy is indicated in patients with DCIS. JCCN 2003; 1:199-206.
16. Edge SB, Shelson DG. Counterpoint: Sentinel lymph node biopsy is not indicated for ductal carcinoma in situ. JCCN 2003; 1:207-212.
17. Lucci A, Jr., Kelemen PR, Miller C III, et al. National practice patterns of sentinel lymph node dissection for breast carcinoma. J Am Coll Surg 2001; 192:453-458.
18. Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 2001; 20:21-35.
19. Silverstein MJ, Cohlan BF, Gierson ED, et al. Duct carcinoma in situ: 227 cases without microinvasion. Eur J Cancer 1992; 28:630-634.
20. Silverstein MJ, Waisman JR, Gamagami P, et al. Intraductal carcinoma of the breast (208 cases). Clinical factors influencing treatment choice. Cancer 1990; 66:102-108.
21. Silverstein MJ, Skinner KA, Lomis TJ. Predicting axillary nodal positivity in 2282 patients with breast carcinoma. World J Surg 2001; 25:767-772.
22. Kinne DW, Petrek JA, Osborne MP, et al. Breast carcinoma in situ. Arch Surg 1989; 124:33-36.
23. Parker RG, Berkbigler D, Rees K, et al. Axillary node dissection in ductal carcinoma in situ. Am J Clin Oncol 1998; 21:109-110.
24. Tunon de Lara C, de Mascarel I, MacGrogan G, et al. Analysis of 676 cases of ductal carcinoma in situ of the breast from 1971 to 1995: diagnosis and treatment-the experience of one institute. Am J Clin Oncol 2001; 24:531-536.
25. de Mascarel I, MacGrogan G, Mathoulin-Pelissier S, et al. Breast ductal carcinoma in situ with microinvasion: a definition supported by a long-term study of 1248 serially sectioned ductal carcinomas. Cancer 2002; 94:2134-2142.
26. Kelly TA, Kim JA, Patrick R, et al. Axillary lymph node metastases in patients with a final diagnosis of ductal carcinoma in situ. Am J Surg 2003; 186:368-370.
27. Winchester DP, Menck HR, Osteen RT, et al. Treatment trends for ductal carcinoma in situ of the breast. Ann Surg Oncol 1995; 2:207-213.
28. Carlson RW, Anderson BO, Bensinger W, et al. NCCN Practice Guidelines for Breast Cancer. Oncology (Huntingt) 2000; 14:33-49.
29. Rivadeneira DE, Simmons RM, Christos PJ, et al. Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: analysis in more than 900 patients. J Am Coll Surg 2000; 191:1-6.
30. Adamovich TL, Simmons RM. Ductal carcinoma in situ with microinvasion. Am J Surg 2003; 186:112-116.
31. Klauber-DeMore N, Tan LK, Liberman L, et al. Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with microinvasion? Ann Surg Oncol 2000; 7:636-642.
32. Wong JH, Kopald KH, Morton DL. The impact of microinvasion on axillary node metastases and survival in patients with intraductal breast cancer. Arch Surg 1990; 125:1298-1301.
33. Silver SA, Tavassoli FA. Mammary ductal carcinoma in situ with microinvasion. Cancer 1998; 82:2382-2390.
34. American Society of Clinical Oncology Joint Committee on Cancer Staging. Cancer Staging Manual, 5th ed. Philadelphia: Lippincott-Raven; 1997.
35. Padmore RF, Fowble B, Hoffman J, et al. Microinvasive breast carcinoma: clinicopathologic analysis of a single institution experience. Cancer 2000; 88:1403-1409.
36. Schuh ME, Nemoto T, Penetrante RB, et al. Intraductal carcinoma. Analysis of presentation, pathologic findings, and outcome of disease. Arch Surg 1986; 121:1303-1307.
37. Patchefsky AS, Schwartz GF, Finkelstein SD, et al. Heterogeneity of intraductal carcinoma of the breast. Cancer 1989; 63:731-741.
38. Rosner D, Lane WW. Should all patients with node-negative breast cancer receive adjuvant therapy? Identifying additional subsets of low-risk patients who are highly curable by surgery alone. Cancer 1991; 68:1482-1494.
39. Solin LJ, Fowble BL, Yeh IT, et al. Microinvasive ductal carcinoma of the breast treated with breast-conserving surgery and definitive irradiation. Int J Radiat Oncol Biol Phys 1992; 23:961-968.
40. Takasaki T, Akiba S, Sagara Y, et al. Histological and biological characteristics of microinvasion in mammary carcinomas < or = 2 cm in diameter. Pathol Int 1998; 48:800-805.
41. Wasserberg N, Morgenstern S, Schachter J, et al. Risk factors for lymph node metastases in breast ductal carcinoma in situ with minimal invasive component. Arch Surg 2002; 137:1249-1252.
42. Silverstein MJ. Ductal Carcinoma in situ of the breast. Philadelphia: Lippincott Williams & Wilkins; 2002.
43. Silverstein M. Ductal carcinoma in situ of the breast, 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2002.
44. Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer - a multicenter validation study. N Engl J Med 1998; 339:941-946.
45. Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996; 276:1818-1822.
46. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003; 349:546-553.
47. Julian TB, Krag D, Brown A, et al. Preliminary technical results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancer patients. Breast Cancer Res Treat 2004; 87(suppl 1):S11-S12.
48. Blanchard DK, Donohue JH, Reynolds C, et al. Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer. Arch Surg 2003; 138:482-487.
49. Pendas S, Dauway E, Giuliano R, et al. Sentinel node biopsy in ductal carcinoma in situ patients. Ann Surg Oncol 2000; 7:15-20.
50. Intra M, Veronesi P, Mazzarol G, et al. Axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. Arch Surg 2003; 138:309-313.
51. Cox CE, Nguyen K, Gray RJ, et al. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS? Am Surg 67:513-519.
52. Moore KH, Tan IK, Cody HS, et al. What is the clinical significance of a positive sentinel node in a patient with DCIS? Ann Surg Oncol 2003; 10(suppl):S57.
53. Zavotsky J, Hansen N, Brennan MB, et al. Lymph node metastasis from ductal carcinoma in situ with microinvasion. Cancer 1999; 85:2439-2443.
54. Wong SL, Chao C, Edwards MJ, et al. Frequency of sentinel lymph node metastases in patients with favorable breast cancer histologic subtypes. Am J Surg 2002; 184:492-498.
55. Intra M, Zurrida S, Maffini F, et al. Sentinel lymph node metastasis in microinvasive breast cancer. Ann Surg Oncol 2003; 10:1160-1165.
56. Buonomo O, Granai AV, Felici A, et al. Day-surgical management of ductal carcinoma in situ (DCIS) of the breast using wide local excision with sentinel node biopsy. Tumori 2002; 88:S48-S49.
57. Hsueh EC, Turner RR, Glass EC, et al. Sentinel node biopsy in breast cancer. J Am Coll Surg 1999; 189:207-213.
58. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989; 63:181-187.
59. Tamhane R, Dahlstrom JE, McCallum DD, et al. The clinical significance of cytokeratin-positive cells in lymph nodes at the time of mastectomy from patients with ductal carcinoma-in-situ. Ann Surg Oncol 2002; 9:999-1003.
60. Lara JF, Young SM, Velilla RE, et al. The relevance of occult axillary micrometastasis in ductal carcinoma in situ: a clinicopathologic study with long-term follow-up. Cancer 2003; 98:2105-2113.
61. Wijsman JH, Broekhuizen LN, Petersen HL, et al. Micrometastases in sentinel lymph nodes of patients with ductal carcinoma in situ have no clinical relevance. Ann Surg Oncol 2004; 11(suppl):S8.
62. El-Tamer MB, Chun J, Gill M, et al. Incidence and clinical significance of lymph node metastasis detected by immuno-histochemical stain in DCIS. Ann Surg Oncol 2004; 11(suppl):S58.
63. Sener SF, Winchester DJ, Martz CH, et al. Lymphedema after sentinel lymphadenectomy for breast carcinoma. Cancer 2001; 92:748-752.
64. Jackman RJ, Burbank F, Parker SH, et al. Stereotactic breast biopsy of nonpalpable lesions: determinants of ductal carcinoma in situ underestimation rates. Radiology 2001; 218:497-502.
65. Burbank F. Stereotactic breast biopsy of atypical ductal hyperplasia and ductal carcinoma in situ lesions: improved accuracy with directional, vacuum-assisted biopsy. Radiology 1997; 202:843-847.
66. Rahusen FD, Meijer S, Taets van Amerongen AH, et al. Sentinel node biopsy for nonpalpable breast tumors requires a preoperative diagnosis of invasive breast cancer. Breast J 2003; 9:380-384.
67. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351:2817-2826.